Objective: The risk of cardiovascular disease increases after menopause. Recent evidence suggests that it is possible for high-density lipoprotein (HDL) to become proatherogenic or dysfunctional in certain situations. Our objective was to evaluate whether the relationship of HDL cholesterol (HDL-C) to subclinical cardiovascular disease differed across the menopausal transition, which would provide insight for this increased risk.
C ardiovascular disease (CVD) is the leading cause of mortality for women. As women age, they are increasingly exposed to high levels of major CVD risk factors, including a poor lipid profile and weight gain. In addition to adverse changes associated with chronological aging, women experience the biological changes of the menopausal transition. Decreasing estrogen levels during the transition have been linked to endothelial dysfunction and larger vessel diameters, markers of early adverse vascular changes. [1] [2] [3] [4] [5] Therefore, the decreased estrogen level after the menopausal transition leaves the vasculature vulnerable to CVD risk factors, such as lipids.
Lipids are known to change in association with both age and the menopausal transition. [6] [7] [8] Understanding these changes, including how they contribute to early vascular disease, may shed light on the underlying mechanisms that increase CVD risk after the transition. During the transition, low-density lipoprotein cholesterol (LDL-C) levels increase, whereas high-density lipoprotein cholesterol (HDL-C) levels tend to remain stable or increase slightly. [9] [10] [11] [12] [13] It is widely accepted that higher levels of LDL-C promote CVD, whereas higher levels of HDL-C are cardioprotective. However, no studies have yet evaluated whether these associations are consistent across the stages of menopause. One study has suggested that the protective effects of high-density lipoprotein (HDL) on IMT may diminish over time in middleaged women. 14 Very recently, some reports have attempted to qualify Bdysfunctional[ HDL and suggest that the antiatherogenic, anti-inflammatory properties of HDL may be lost in certain inflammatory conditions. [15] [16] [17] [18] [19] [20] However, one-time measures of lipids may not fully evaluate the complex nature of triglyceride exchanged between HDL-C and LDL-C and its potential effect on subclinical CVD; therefore, exploration beyond HDL-C and LDL-C is required. 21 The Study of Women's Health Across the Nation (SWAN) provides a unique opportunity to determine if the relationship between lipids and subclinical CVD varies by menopause status. SWAN explored biological changes as women transitioned through menopause. SWAN Heart, an ancillary study of SWAN, collected subclinical CVD measures in two of the seven parent study sites. Subclinical CVD measures are reliable measures of the atherosclerotic process. 22 Accordingly, the purpose of this study was to evaluate whether the menopausal transition modifies the contribution of lipids to subclinical CVD risk. Understanding the mechanisms that promote early CVD in women may lead to new preventive efforts or treatments to delay CVD in the postmenopausal years.
METHODS

Study population
SWAN is a multicenter, community-based, longitudinal study. Baseline enrollment of 3,302 women between the ages of 42 and 52 years occurred during 1996 to 1997. A detailed description of the study design and recruitment has previously been published. 23 Only women who had an intact uterus and at least one ovary, menstruated in the prior 3 months, and not taken hormone therapy or oral contraceptives in the prior 3 months were eligible for the parent project. Women who were pregnant or breast-feeding were excluded. The ancillary study, SWAN Heart, evaluated 608 women for subclinical CVD from two SWAN sites (Pittsburgh and Chicago). Baseline enrollment occurred between 2001 and 2003 (corresponding to the fourth to seventh annual SWAN visits, respectively). Women were excluded from this analysis for CVD history (n = 2), hysterectomy/oophorectomy (n = 16), diabetes (n = 1), and hormone therapy use (n = 32). An additional 17 women were excluded because of missing menopause status or subclinical CVD data, resulting in a final sample size of 540 (89%) for this analysis. The site-specific institutional review boards approved research protocols, and all women provided informed consent forms before enrollment.
Subclinical measures
Aortic calcification (AC) and coronary artery calcification (CAC) were quantified using electron beam CT (EBCT; GE Imatron C-150 Ultrafast CT Scanner, San Francisco, CA). Participants were exposed to 2.45 rads during the aortic scan and 0.783 rads during the coronary scan. All scans were saved to an optical disk and read centrally at the University of Pittsburgh using a DICOM workstation and Acuimage software (South San Francisco, CA). Using the Agatston scoring method, three contiguous pixels greater than 130 Hounsfield units were used to define the presence of calcified lesions within the vessel. A total calcium score was calculated by summing the calcium scores in the four major coronary arteries (left main, left anterior descending, left circumflex, and right coronary artery), whereas the aorta total score was from the whole aortic vessel. One blinded physician, centrally trained in EBCT with a standardized protocol, analyzed all scans from the two sites. A reproducibility study conducted by the Pittsburgh, PA, EBCT image reading center in 40 consecutive participants previously reported an intrareader intraclass correlation of 0.98 for AC and 0.99 for CAC. 24 Carotid intima media thickness (IMT) and carotid plaque assessments were made using B-mode ultrasound (Pittsburgh site: Toshiba American Medical Systems, Tustin, CA; and Chicago site: Hewlett Packard, Andover, MA). Sonographers were centrally trained with a standardized protocol. Right and left carotid arteries were scanned to obtain a total of eight images: near and far wall of the common carotid (1 cm proximal to the bulb), far wall of the carotid bulb (starting from the point where the common carotid walls are no longer parallel and ending at the flow divider), and far wall of the internal carotid artery (distal 1 cm from the flow divider). Semiautomated reading software (AMS system developed in Sweden by Dr. Thomas Gustavsson) generated approximately 140 measurements of IMT from the leading edge of the intima to the trailing edge of the media for each 1-cm segment. The mean IMT of each of the eight carotid segments was determined, and the average of these eight mean measures was computed for the outcome variable in this analysis. Carotid plaques were identified as discrete focal protrusions into the lumen greater than 50% of the surrounding wall thickness. Images obtained from the comparable ultrasound machines were read centrally at the University of Pittsburgh Ultrasound Research Laboratory (Pittsburgh, PA). Interreader reproducibility of IMT and carotid plaque during annual recertifications for the Ultrasound Research Laboratory was as follows: intraclass correlation of 0.98 for IMT and 0.86 to 0.93 for plaque. [25] [26] [27] 
Covariate measures
During annual visits in SWAN, standard questionnaires were administered, fasting blood samples were collected, and anthropometric measures and blood pressure readings were obtained. In this cross-sectional analysis, data from these annual SWAN clinic visits (fourth visit, n = 272; fifth visit, n = 231; sixth visit, n = 20; and seventh visit, n = 17) were matched to participant's baseline SWAN Heart subclinical measures. Based on self-reported bleeding history, menopause status was classified as premenopausal (Pre; menses in the last 3 months with no irregularity), early perimenopausal (EP; menses in the last 3 months with irregularity), late perimenopausal (LP; no menses for at least 3 months but G12 months), and postmenopausal (Post; no menses for at least 12 months).
Fasting blood samples were analyzed at the Medical Research Laboratories (Lexington, KY). EDTA-treated plasma was used to analyze lipids; isolation of HDL-C (mg/dL) was done with heparinY2 M manganese chloride, and LDL-C (mg/dL) was estimated with the Friedewald equation. 28 For a subset of Pittsburgh SWAN Heart women, lipoprotein subclasses were available from blood samples collected in 1997 to 2001. Lipoprotein subclasses were determined using stored EDTA plasma using an automated nuclear magnetic resonance spectroscopic assay (LipoScience Inc., Raleigh, NC), with a modification of the method previously reported. 29, 30 The following lipoprotein concentrations were analyzed: total low-density lipoprotein (LDL) and HDL particle concentrations (LDL-P in nmol/L and HDL-P in Kmol/L), large LDL-P and HDL-P concentrations, and small LDL-P and HDL-P concentrations. Large LDL-P diameters are defined as 21.2 to 23 nm; small LDL-P, as 18 to 21.2 nm; large HDL-P, as 8.8 to 13 nm; and small HDL-P, as 7.3 to 8.2 nm. The total number of HDL-P = preA HDL-P + small HDL-P + large HDL-P; nuclear magnetic resonance technology cannot quantify preA HDL-P, and thus, total HDL-P derived by adding small HDL-P + medium HDL-P + large HDL-P may underestimate total HDL-P. However, preA HDL-P is usually less than 5% of total HDL-P, and thus, most studies do not look at it. Total LDL-P and total HDL-P are the sum of small + large LDL-P and small + large HDL-P, respectively. Mean LDL-P and HDL-P sizes are weighted averages (ie, the diameter of each subclass multiplied by its relative concentration). A total of 71 SWAN Heart women had both lipoprotein subclass data and subclinical CVD measures available. Those with lipoprotein data collected more than 16 months apart from their subclinical measures were excluded from this analysis. Of the remaining 53 women, average collection time from subclinical measures was 184.5 days for Pre/EP and 236.3 days for LP/Post women.
Statistical analysis
The distribution of each continuous variable was examined, and variables were log transformed or categorized if the distribution was not approximately normal. Glucose and triglycerides were log transformed; however, medians (interquartile range) are presented in Tables 1 and 3 for descriptive purposes. Alcohol consumption, AC, CAC, and carotid plaque were identified as having skewed distributions and large proportions of zero values. Alcohol consumption was grouped into zero drinks and one drink or more. Single-vessel CAC (left main, left anterior descending, left circumflex, and right coronary artery) and carotid plaque were dichotomized into none or any, given the small sample of women with any disease, and AC and total CAC were classified as none, moderate, and high calcification scores (AC: 0, 1-74, and Q75; and CAC: 0, 1-7.54, and Q7.55, respectively). Because of the low levels of calcification, high AC and CAC were defined as the 75th percentile or greater, as reported by prior SWAN articles, to allow for analysis between high and low calcification, which is similar to studies with low calcification burden. 31, 32 Menopausal status was dichotomized into Pre/EP and LP/Post to maintain a moderate sample size as previously reported. 4 All remaining variables met the guidelines for normality and were treated as continuous. Two-sample t test and W 2 test were used to compare participant characteristics between Pre/EP and LP/Post women.
Interactions between lipids and menopause status were tested in multivariable models with and without adjustments for other covariates. Further explorations of the lipid interactions were done using a reparameterized model to include the effects of the lipid among Pre/EP and LP/Post women in a single multivariable model (subclinical measure = menopause status + effect of the lipid for Pre/EP women + effect of the lipid for LP/Post women + covariates). Multivariable regression models were used to assess the association between traditional CVD risk factors and AC, CAC, singlevessel CAC, carotid plaque, and IMT. For AC and CAC, multinomial logistic regression rather than ordinal logistic regression was preferred because of unmet assumptions of proportional odds. 33 No AC and no CAC were the reference groups for the multinomial logistic regression. No single-vessel CAC and no carotid plaque were the reference groups for the binary logistic regression. Preliminary analyses used stepwise regression selection to evaluate the inclusion of traditional CVD risk factors in the multivariable linear and logistic regression models with default P = 0.15 entry and exit thresholds. Final models were adjusted for known CVD risk factors and confounders: age, site, race, systolic blood pressure (SBP), glucose, body mass index, smoking, menopause status, and lipids (HDL-C, LDL-C, or triglycerides). The subsample of Pittsburgh women (n = 53) with available lipoprotein subclass data was correlated with triglycerides using Spearman correlations and compared across menopause status using a two-sample t test. The lipoprotein data were not used in the regression analysis because of the small sample size and inability to adjust for known confounders. All statistical analyses were completed with SAS 9.1. Two-sided P e 0.05 was considered statistically significant.
RESULTS
Of the 540 SWAN Heart participants included in this analysis, 316 (59%) were Pre/EP and 224 (41%) were LP/Post women ( Table 1 ). Average age was 50 years, with Pre/EP women being 3 years younger than LP/Post women. LP/Post women had higher mean HDL-C level, LDL-C level, triglyceride level, SBP, and glucose level compared with Pre/EP women. After age adjustment, mean HDL-C level and SBP no longer differed significantly. In addition, LP/Post women had more AC, CAC, and carotid plaque and higher IMT, on average; however, once adjusted for age, only carotid plaque differed between the two groups.
The effect of menopause status on the relationships between lipids (HDL-C, triglyceride, and LDL-C) and subclinical atherosclerosis is shown in Table 2 . To better visualize the multiple interactions found with HDL-C, the data are also presented in Figure 1 . For CAC, only the results for total and left main vessel were included in this article because the effect of lipids on calcification did not vary by menopause status in the other three vessels measured. In the multivariable models adjusted for age, site, race, HDL-C, LDL-C, SBP, glucose, body mass index, and smoking, the effect of HDL-C varied by menopause status for high AC, any left main CAC, any carotid plaque, and IMT. The relationship of triglyceride to AC was stronger for Pre/EP women, whereas LDL-C was more strongly related to carotid plaque and IMT among LP/Post women. For every 1-mg/dL increase in HDL-C level, the odds of high AC among Pre/EP women were decreased by 3%, whereas the odds for LP/Post women were increased by 3%. Similarly, among LP/Post women, the odds of any left main CAC were increased by 8% for every 1 mg/dL of HDL-C. The pattern of HDL-C being protective for Pre/EP women, but not for LP/Post women, was also seen in any carotid plaque and IMT. The pattern for log of triglycerides was reversed with an increased risk for AC among Pre/EP women, whereas LDL-C was associated with higher odds of any carotid plaque among LP/Post as compared with Pre/EP women, and an increase of 0.0004 mm in IMT was observed among LP/Post women for every 1 mg/dL of LDL-C. Of note, similar to LDL-C, non-HDL-C and apolipoprotein B (ApoB) were also associated with thicker IMT among LP/Post, but not Pre/EP, women (data not shown).
An exploratory analysis using the lipoprotein subclass data for a subset of the study population evaluated potential mechanisms for differences in lipid effects with menopause. LP/Post women (n = 34) had significant differences in their lipoprotein subclass profile compared with Pre/EP women (n = 19; Table 3 ). LP/Post women had more small HDL-P, more total HDL-P, and a smaller mean HDL-P size, on average. In addition, LP/Post women had significantly higher triglyceride and LDL-C levels and more total LDL-P than did Pre/EP women. Finally, the correlations between lipoproteins and triglycerides among the SWAN Heart women were tested given the known dynamic exchange of triglyceride during HDL-C and LDL-C remodeling. All of the lipoprotein subclass measures except large HDL-P (borderline), large LDL-P, and mean LDL size (borderline) were significantly correlated with triglycerides.
DISCUSSION
Evaluation of the interactions between menopause status and HDL-C for AC (P = 0.01), left main CAC (P = 0.1), carotid plaque (P = 0.08), and IMT (P = 0.06) suggests that the atheroprotective effect of HDL may be weaker in postmenopausal women, whereas the effect of LDL-C was stronger among postmenopausal women for IMT (0.05). Higher HDL-C levels were associated with higher levels of high AC and any left main CAC in LP/Post women after adjustments for traditional risk factors, whereas higher HDL-C levels had a traditionally protective effect for high AC, any carotid plaque, and IMT in Pre/EP women. These results are in accord with those of Fan and Dwyer, 14 who reported that IMT progression in postmenopausal women was directly associated with HDL-C, adjusted for CVD risk factors. Among the men in that study, there was the expected inverse association between IMT progression and HDL-C, suggesting that the phenomenon for LP/Post women in this SWAN Heart analysis may be due to changes occurring with the menopausal transition rather than just age. A detrimental effect of HDL-C among postmenopausal women was also reported in the EURO-STROKE study, which found that among women pooled from the Novosibirsk and Rotterdam cohorts, a higher HDL-C level was associated with increased odds of stroke. 34 The average age of the cohorts was 51.6 and 72.8 years, respectively; therefore, these effects were seen among women who have recently transitioned through menopause and those who have been postmenopausal for years.
The reduced or reversed CVD risk association with HDL-C postmenopause may be explained by functional and compositional changes in HDL. 29 SWAN is one of the few studies that has a large enough sample size with sufficient follow-up to differentiate the effects of menopause from those of aging, and it has recently been shown that although triglycerides increased with age, only total cholesterol, LDL-C, and ApoB showed a substantial increase specifically with menopause. 8 In contrast, HDL-C levels increased acutely before menopause and decreased after menopause. Given that conventional methods of measuring HDL-C and LDL-C levels reflect the concentration of cholesterol carried by the lipoprotein particles rather than the concentration of the particles themselves and that lipoprotein particles are believed to provide more information in predicting CVD, evaluation of lipoproteins and lipoprotein subclasses may provide additional insight into the association between lipids and CVD. 35, 36 Data on menopause-specific effects on lipoproteins and lipoprotein subclass distribution are very sparse. Cross-sectional data from the Framingham Offspring Study did not specifically look at menopause but demonstrated the complex interrelationships between lipids, lipoproteins, lipoprotein subclasses, and mean particle sizes. 29 The Framingham Offspring Study data also showed that these relationships differ with age and for women compared with men. For example, in women, LDL-C level increases with age, surpassing LDL-C level in men by about age 60 years, but total LDL-P in women does not equal that in men until about the age of 75 years, and small LDL-P levels in women remain substantially lower compared with those in men throughout the age span. Among women, HDL-C levels show a slight decline with age, similar to large HDL-P, whereas total HDL-P and intermediate and small HDL-P increase substantially with age, possibly accelerating around menopause. For women, both large and small LDL-P and medium and small HDL-P seem to increase more at around age 50 years than at other ages. 29 In epidemiological studies, CVD often, but not always, has a stronger inverse association with larger HDL-Ps or the cho-lesterol carried by larger HDL-Ps. 37, 38 The large Women's Health Study (WHS) also found that large HDL-P was significantly associated with reduced CVD incidence, whereas small HDL-P was not. 39 However, the WHS was a mixture of premenopausal and postmenopausal women, and the CVD incidence was also statistically significantly related to all LDL and very-low-density lipoprotein subclass concentrations, highlighting the difficulty of attributing risk to any one lipid or lipoprotein measure given their dynamic metabolic interrelationships. Among postmenopausal women, the Healthy Women Study reported a significant protective association between CAC and large HDL-P and HDL-P size, whereas large very-low-density lipoprotein particle and small and total LDL-P were associated with higher CAC levels, but small HDL-P levels were not correlated with CAC. 40 In addition, postmenopausal women with AC or CAC had lower levels of (larger) HDL 2 -C and higher levels of (smaller) HDL 3 -C. 41 In our subset with lipoprotein subclass data, LP/Post women had more small HDL-P and smaller HDL-P size, on average, compared with Pre/EP women, but they also had higher levels of total LDL-P and LDL-C. The inverse correlation between triglycerides and large HDL-P and the direct correlation with small HDL-P suggest that as triglycerides increase, as seen with the menopausal transition, fewer large HDL-P and more small HDL-P are circulating. In addition, more total LDL-Ps are observed with higher triglyceride levels. These results are consistent with those of the WHS. 39 Any or all of these interrelated changes in the lipoprotein profile around menopause could potentially explain our findings that HDL-C level was not inversely associated with subclinical atherosclerosis among postmenopausal women.
Interpretation of HDL-P size may not be the only explanation for these observed associations given the dynamic relationship between HDL-C, LDL-C, and triglyceride exchange. 21 A recent study exploring the relationship between HDL-C and the risk of CVD in postmenopausal women found that subpopulations of triglyceride-rich lipoproteins and HDL were better predictors of disease than were triglycerides and HDL-C concentrations, suggesting that differences in HDL lipoproteins may be directly related to triglycerides. The triglyceride interaction with menopause status for AC in the SWAN Heart suggests that triglyceride may be a stronger risk factor among Pre/EP women compared with LP/Post women. The relationship between the lipoproteins and triglycerides showed that higher triglyceride levels, as seen in LP/Post women, is correlated with lower HDL-C level, more small HDL-P, less large HDL-P, and smaller HDL size. In addition, triglyceride levels were positively correlated with LDL-C level and total and small LDL-P. Therefore, changes in triglyceride levels may be the driving force for the reduced or reversed HDL-C associations with subclinical CVD and lipoprotein profile among postmenopausal women observed in our study. Furthermore, this relationship may also be due to concurrent and related changes in LDL-C level. The association of CVD risk and reduced large HDL-P implies causality when it may simply be an indicator for elevated ApoB or total LDL-P. In this study, the association of LDL-C with carotid plaque and IMT was larger for LP/Post women, potentially indicating that LDL-C is a stronger risk factor among postmenopausal women. LP/Post women had higher triglyceride and LDL-C levels and total LDL-P compared with Pre/EP women. This agrees with our recent report from the entire SWAN study, which used longitudinal data to demonstrate that menopause increases ApoB, a measure highly correlated with total LDL-P, along with total cholesterol and LDL-C. 8 Differences in the dynamic flux between lipids and lipoproteins across the menopausal transition status need further exploration.
Another potential mechanism responsible for these lipoprotein profile changes is enzymatic activity. Large HDL-Ps are converted to small HDL-Ps by increased hepatic lipase. 42 Estrogen inhibits hepatic lipase; therefore, decreases in estrogen with menopause should lead to a higher ratio of small HDL-P to large HDL-P and smaller mean HDL-P size. In support of this theory, postmenopausal women have been found to have higher hepatic lipase activity that covaried inversely with large HDL-P. 42 In addition, increasing insulin resistance with age may contribute to lower lipoprotein lipase activity, which is a determinant of lower HDL-C level, and in concert with hepatic lipase as a determinant of lower levels of cholesterol carried by the larger HDL 2 -Ps. 43 In addition to increasing hepatic lipase, decreased estrogen levels with menopause hinder several protective vascular mechanisms. Estrogen is believed to accelerate reendothelialization in the face of vascular injury, thereby inhibiting smooth muscle proliferation and, subsequently, medial thickening. 44 Vascular tone is maintained by estrogen through several pathways, including nitric oxide and prostacyclin. 2 Therefore, decreased estrogen levels after the menopausal transition leave the vasculature vulnerable to CVD risk factors, such as lipids. SWAN Heart has previously shown that lower estrogen levels are directly related to larger carotid arterial diameter among women not taking exogenous estrogen therapy. 4 Larger vessel diameters lead to less ability to compensate for hemodynamic changes because of blood pressure or arterial wall thickening and thus leave the vessel more vulnerable. 45 Thus, not only are postmenopausal women at increased risk for CVD as estrogen decreases, but also they are exposed to poorer lipid profiles, which may add to their risk.
The lipoprotein subclass data presented here provide initial evidence in support of lipoprotein compositional changes as a potential mechanism underlying the observed associations between HDL-C and subclinical CVD measures. In addition, this study supports other research showing functional changes in HDL, such as HDL can become proinflammatory or proatherogenic in some circumstances. [15] [16] [17] [18] [19] However, this is a preliminary, cross-sectional analysis, and thus, a causal relationship between change in menopause status and HDL cannot be inferred. Furthermore, evaluating lipoprotein-associated risk is difficult because of the interrelationships between lipids and lipoprotein levels. 21 It is plausible that the lipid changes attributed to the menopausal transition may instead be explained by altered lipid and lipoprotein patterns due to premature and early menopause. 45 Premature and early menopause incidence ranged from 1% to 1.4% and 2.9% to 3.7%, respectively, in SWAN white and African American women. 46 Despite the modest sample size for detecting interactions, the HDL-CYbyYmenopause status interaction was significant for AC and borderline for left main CAC, carotid plaque, and IMT; borderline for triglyceride and menopause status for AC; and significant for LDL-C and menopause status for IMT, suggesting differential effects by menopause status. Left main coronary artery stenosis is known to be an independent risk factor for individuals with coronary artery disease and, therefore, may be the reason why a difference in the effect of HDL-C was observed only in the left main coronary artery. 47, 48 The low prevalence of moderate to high CAC burden (2.4% with CAC score 9100) observed in the SWAN Heart cohort may explain the nonsignificant findings for CAC. 31 Further studies need to be conducted in a population with more extensive coronary artery disease. The mean carotid artery IMT across carotid segments rather than the mean common carotid artery IMT was used because it may better capture early atherosclerosis among these relatively young women, but this should be considered when these data are compared with other published results. 49 Lastly, because all participants did not have lipoprotein subclass data, lipoproteins could not be used in the regression models, and associations between lipoprotein and subclinical disease could not be directly analyzed.
CONCLUSIONS
In conclusion, these results suggest that the protective effect of HDL is reduced among postmenopausal women, possibly related to changes in the lipoprotein subclass profile seen with the menopausal transition. This decreased estrogen and adipose tissue redistribution, in addition to a more vulnerable vessel caused by aging, may partially explain the increased CVD risk seen after menopause. Future studies evaluating lipid and lipoprotein profiles longitudinally through the menopausal transition are needed.
